Last reviewed · How we verify
Ixabepilone (Ixempra)
Ixabepilone stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division.
Ixabepilone stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division. Used for Metastatic or locally advanced breast cancer (in combination with capecitabine or as monotherapy), Taxane-resistant breast cancer.
At a glance
| Generic name | Ixabepilone (Ixempra) |
|---|---|
| Also known as | Ixempra, azaepothilone B, BMS-247550 |
| Sponsor | SCRI Development Innovations, LLC |
| Drug class | Microtubule-stabilizing agent |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ixabepilone is a microtubule-stabilizing agent that binds to β-tubulin and promotes microtubule assembly while inhibiting depolymerization. This leads to cell cycle arrest in the G2/M phase and triggers apoptosis in cancer cells. Unlike taxanes, ixabepilone can overcome certain resistance mechanisms and remains effective against some taxane-resistant tumors.
Approved indications
- Metastatic or locally advanced breast cancer (in combination with capecitabine or as monotherapy)
- Taxane-resistant breast cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Fatigue
- Myalgia/arthralgia
- Nausea
- Diarrhea
- Alopecia
Key clinical trials
- Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. (PHASE2)
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy (PHASE2)
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (PHASE2)
- Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer (PHASE1, PHASE2)
- Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
- Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab (PHASE2)
- BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |